A Maryland-based biotechnology company announced the initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate.
Novavax, Inc. stated on December 28, 2020; the Phase 3 trial has begun enrolling adult volunteers into the randomized, placebo-controlled trial, which intends to enroll approximately 30,000 people at about 115 sites.
Read More
